Funding
Funding not disclosed
Founders
Product
Problem
Autologous cell therapies, while promising, face limitations in accessibility due to complex and expensive centralized manufacturing processes. This restricts patient access and increases the overall cost of treatment.
Solution
Exthymic is developing point-of-care manufacturing techniques to democratize access to autologous cell therapies. By decentralizing the production process, Exthymic aims to reduce the logistical complexities and costs associated with traditional cell therapy manufacturing. This approach enables faster turnaround times and broader availability of personalized cell-based treatments. The company's technology seeks to streamline the manufacturing workflow, making these therapies more accessible to a wider patient population.
Target Audience
The primary target audience includes hospitals, clinics, and research institutions involved in delivering autologous cell therapies.
Features
- Point-of-care manufacturing platform for autologous cell therapies
- Decentralized production model to reduce costs and logistical hurdles
- Streamlined manufacturing workflow for faster turnaround times